Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Recurrent Squamous Cell Lung Carcinoma 2Melanoma 2Hodgkin Disease 2Thymoma 1Small Cell Lung Carcinoma 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Inoperable œsophageal Cancer 1Gastric and Esophagogastric Junction Adenocarcinoma 1Diabetes Mellitus, Insulin-Dependent, 12 1Colorectal Neoplasms 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1Brain Neoplasms 1Advanced Solid Tumors 1Adenocarcinoma 1

Interventions

Nivolumab 1Ipilimumab 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Gastric and Esophagogastric Junction Adenocarcinoma × Nivolumab × Clear all
NCT03443856 2024-01-05

VESTIGE

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Active not recruiting
197 enrolled
Gastrointestinal

Gastric and Esophagogastric Junction Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡